[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100464976","phase-1-expanded-haploidentical-natural-killer-cells-as-consolidation-strategy-for-childrenyoung-adults-with-aml-100464976",false,"NCT05334693","Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children\u002FYoung Adults With AML","Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children\u002FYoung Adults With AML","Inclusion Criteria:\n\nPatients:\n\n* primary intermediate risk AML in molecular complete remission;\n* primary high risk AML in molecular complete remission awaiting unrelated HSCT;\n* Karnofsky or Lansky performance scale greater or equal to 70;\n* written informed consent.\n\nDonors:\n\n* haploidentical family donor;\n* donor suitable for cell donation and apheresis according to standard criteria;\n* written informed consent.\n\nExclusion Criteria:\n\nPatients:\n\n* uncontrolled infection;\n* severe hepatic dysfunction: SGOT or SCPT \\>=5x upper limit of normal for age;\n* positive serology for human immunodeficiency virus (HIV).\n\nDonors:\n\n* pregnancy;\n* positive serology for HIV, hepatitis B or C.","ALL","6 Months","21 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children\u002Fyoung adults with intermediate risk AML.",[28],"Acute Myeloid Leukemia",[30,31],"Natural killer cells","Immunotherapy","RECRUITING","2024-08-27",{"date":35,"type":36},"2024-08-28","ACTUAL",{"date":38,"type":36},"2021-11-01",{"date":40,"type":21},"2026-06",{"name":42,"class":43},"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100464869","phase-1-pilot-car-t-cells-therapy-for-childrenyoung-adults-with-cd19-rr-leukemialymphoma-100464869","NCT05333302","Pilot CAR-T Cells Therapy for Children\u002FYoung Adults With CD19+ R\u002FR Leukemia\u002FLymphoma","Pilot Study of CD19 CAR-T Cells Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia\u002FLymphoma in Children\u002FYoung Adults","Inclusion Criteria:\n\n* CD19+ relapsed or refractory lymphoblastic leukemia\u002Flymphoma;\n* Karnofsky or Lansky performance scale greater or equal to 70;\n* T-cells count in peripheral blood \\>150 cells\u002FµL;\n* Written informed consent.\n\nExclusion Criteria:\n\n* primary immunodeficiencies or genetic syndromes;\n* neurologic diseases;\n* autoimmune diseases or polyallergie;\n* transfusion of donor lymphocyte less than 6 week before CAR-T cells infusion;\n* GvHD grade 2-4;\n* uncontrolled systemic infection;\n* hypoxia (Sp02\\\u003C90%)\n* severe hepatic dysfunction: ALT or AST \\>=3x upper limit of normal for age;\n* renal dysfunction: serum creatinine level \\>=3x upper limit of normal for age;\n* positive serology for human immunodeficiency virus (HIV), active hepatite C or B;\n* pregnancy.","1 Year","30 Years",{"count":55,"type":21},10,[24],"The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children\u002Fyoung adults with relapsed or refractory acute lymphoblastic leukemia\u002Flymphoma.",[59,60],"B-cell Acute Lymphoblastic Leukemia","Lymphoblastic B-Cell Lymphoma",[62,63,64],"immunotherapy","CAR-T cells","CD19",{"date":35,"type":36},{"date":67,"type":36},"2020-10-26",{"date":69,"type":21},"2025-06",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":87,"locationsCount":44},"100460182","phase-1-immunotherapy-with-ex-vivo-expanded-haploidentical-natural-killer-cells-for-childrenyoung-adults-with-aml-100460182","NCT05272293","Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children\u002FYoung Adults With AML","Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children\u002FYoung Adults With High-risk, Refractory or Relapsed AML","Inclusion Criteria:\n\nPatients:\n\n* primary high risk AML\n* primary refractory AML\n* relapsed AML\n* Karnofsky or Lansky performance scale greater or equal to 70\n* written informed consent\n\nDonors:\n\n* haploidentical family donor\n* donor suitable for cell donation and apheresis according to standard criteria\n* written informed consent\n\nExclusion Criteria:\n\nPatients:\n\n* uncontrolled infection\n* severe hepatic dysfunction: SGOT or SCPT \\>=5x upper limit of normal for age\n* positive serology for human immunodeficiency virus (HIV)\n\nDonors:\n\n* pregnancy\n* positive serology for HIV, hepatitis B or C",{"count":20,"type":21},[24,25],"The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children\u002Fyoung adults with primary high risk or refractory AML and relapsed AML.",[28],[83],"Natural killer cells, immunotherapy",{"date":35,"type":36},{"date":38,"type":36},{"date":40,"type":21},{"name":42,"class":43},""]